About ABBV-744 as a potential therapeutic option for aggressive cancers
These side effects had been notably milder when compared with an inhibitor of both bromodomains. A detailed molecular Investigation also revealed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen TaylorFor all flow cytometry experiments, 10,000 cells for every replicate ended up analyzed,